Recent News

SOHO 2021: Optimizing Treatment for Older Patients With AML

SOHO 2021: Novel Combination Therapy Under Study in Newly Diagnosed AML

SOHO 2021: Adding Azacitidine to FLAG Chemotherapy in AML

SOHO 2021: Early Results With Magrolimab Plus Azacitidine in AML

Is Chemotherapy Linked to Deterioration of Oral Health in Patients With AML?

One Man’s Experience With AML, COVID-19, and Allo-HSCT

Can Romyelocel-L Plus G-CSF Reduce Infections in Patients With AML?

Can MRD Guide Postremission Treatment Decisions in Intermediate-Risk AML?

Mixed Results Emerge in Phase II Selinexor Trial in Older Patients With Resistant AML

Novel Monoclonal Antibody and Chemotherapy Combination Under Study in Resistant AML

Japanese Subgroup Analysis of BCL2 Inhibitor Plus Low-Dose Cytarabine in Untreated AML

COVID-19 and Leukemias: Focus on Risk Factors for Poor Outcomes

Absolute Monocyte and Lymphocyte Counts in AML: Prognostic Significance at the Time of Relapse

Is the Presence of RUNX1 Mutations an Adverse Risk Factor in AML?

Anti-CD117 Monoclonal Antibody Plus Nonmyeloablative Conditioning in Older Patients With AML

FDA Brief: SNDX-5613 Receives Fast Track Designation for Certain Resistant Acute Leukemias

ASCO 2021: Exploring the Molecular Architecture of Extramedullary AML

EHA2021: Correlating MRD and Outcomes With Venetoclax and Azacitidine in AML

ASCO 2021: Early-Phase Results of Anti-CLL1–Based CAR T-Cell Therapy in Children With AML

EHA2021: Venetoclax Plus Gilteritinib Under Study in Resistant FLT3-Mutated AML

ASCO 2021: Time-Limited Use of Aspacytarabine for Patients With AML Who Are Unfit for Chemotherapy

EHA2021: Post Hoc Analysis of Oral Azacitidine in AML From QUAZAR AML-001 Trial

ASCO 2021: Novel FLT3 Inhibitor Under Study in Resistant AML

ASCO 2021: Interim Analysis of Phase II Trial of Olutasidenib in IDH1-Mutant AML

Australian Researchers Use Novel Work Utility Measure to Assess Productivity Impact of AML

Trousseau Syndrome and AML: Case Report

Venetoclax-Based Therapy and Azole Antifungals in AML: Effects on Blood Cell Counts

Quizartinib Combinations Under Study in FLT3-ITD–Mutated AML

Whole-Genome Sequencing for Genetic Profiling in Myeloid Cancers

Pilot Study in AML: Can Biomarkers Predict Chemotherapy-Related Infection?

Dactinomycin Under Study in Management of Resistant NPM1-Mutated AML

Have Outcomes in AML Improved Over the Past 40 Years?

CPX-351 for High-Risk AML: Phase III Post Hoc Analysis

AACR 2021: Daratumumab Plus Venetoclax Under Study in AML

Chemotherapy Intensity, MRD Status, and Outcomes in AML

AACR 2021: Is SIRT5 Enzyme Potential Therapeutic Target in AML?

Optimal Number of Chemotherapy Courses for Younger Patients With AML

Testing for Germline Mutations in Elderly Patients With AML

Green Tea Treatment in Elderly Patients With Myelodysplasia-Related AML

Comparison of Hypomethylating Agent Plus Venetoclax With CPX-351 in Secondary AML

Predicting Response to Venetoclax Combination Therapy in Resistant AML

Revised Label Approved by FDA for Daunorubicin/Cytarabine Combination for AML

Case Report: Central Diabetes Insipidus and AML